Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that ...

The global primary sclerosing cholangitis (PSC) market is on an impressive growth trajectory, with forecasts estimating a market valuation of USD 314.26 million by 2033. This robust expansion is ...

Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today ...

Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across ...

About Primary Sclerosing Cholangitis Primary Sclerosing Cholangitis ... or interventional therapy to halt the progression of disease. A liver transplant is the only known long-term treatment ...

Esperion announced the expansion of its development portfolio with a new program aimed at treating primary sclerosing cholangitis (PSC), a rare liver disease. The company confirmed the ...

Similar findings were seen in other biochemical liver ... primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver ...

Primary Sclerosing Cholangitis (PSC) is a rare, progressive, cholestatic, immune‐mediated disease of the bile ducts. Bile ducts carry the digestive liquid bile from the liver to the small intestine.

1 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes, T Snir, R Greenman, R Aricha, I Vaknin, M Frankel ...